Sign In
Buy CORT
$72.65
+1.45 (+2.04%)
At Close: Jun 03, 2026
5 Stocks With Recent Price Strength to Tap Wall Street Rally
09:00am, Tuesday, 22'nd Oct 2024
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are IDR, QFIN, SEZL, CORT, FINW.
Strength Seen in Corcept (CORT): Can Its 5.5% Jump Turn into More Strength?
04:46am, Monday, 21'st Oct 2024
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Wall Street Analysts See a 43.01% Upside in Corcept (CORT): Can the Stock Really Move This High?
10:55am, Thursday, 17'th Oct 2024
The mean of analysts' price targets for Corcept (CORT) points to a 43% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i
Corcept (CORT) Is a Great Choice for 'Trend' Investors, Here's Why
09:50am, Thursday, 17'th Oct 2024
If you are looking for stocks that are well positioned to maintain their recent uptrend, Corcept (CORT) could be a great choice. It is one of the several stocks that passed through our "Recent Price S
Corcept: Key Announcements Coming Soon
09:43am, Tuesday, 15'th Oct 2024
Corcept's upcoming Q4 announcements include pivotal trial results for Relacorilant in ovarian cancer, Dazucorilant in ALS, and an NDA filing for Relacorilant in Cushing's. Positive results from these
5 Stocks With Recent Price Strength Amid October Volatility
06:11am, Friday, 11'th Oct 2024
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ATAT, VRT, CORT, QFIN, ADMA.
3 Strong Buy Momentum Stocks as Bull Market Nears 2-Year Mark
04:08pm, Wednesday, 09'th Oct 2024
Stocks like Corcept Therapeutics, Abercrombie & Fitch and HCI Group have been selected as the momentum picks for the day using the Driehaus strategy.
Here's Why Investors Should Consider Buying Corcept Stock Now
09:50am, Wednesday, 02'nd Oct 2024
Here, we are discussing some reasons why investing in CORT stock now may turn out to be a prudent move.
Wall Street Analysts Think Corcept (CORT) Could Surge 41.31%: Read This Before Placing a Bet
10:56am, Tuesday, 01'st Oct 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 41.3% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positi
Here's Why Momentum in Corcept (CORT) Should Keep going
09:50am, Tuesday, 01'st Oct 2024
If you are looking for stocks that are well positioned to maintain their recent uptrend, Corcept (CORT) could be a great choice. It is one of the several stocks that passed through our "Recent Price S
Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast
03:01pm, Monday, 30'th Sep 2024
Truist Securities raised the price target for Corcept Therapeutics Incorporated CORT and cites continued momentum in Korlym sales more than a decade after launch amid increasing competition and says i
3 Small Biotech Stocks With The 'Big Mo' Right Now
12:54pm, Thursday, 19'th Sep 2024
Three small biotech stocks that I have covered lately have shown significant upward movement recently due to positive news. The stocks are experiencing what I call the 'Big Mo,' indicating strong mome
Corcept (CORT) Moves 6.5% Higher: Will This Strength Last?
08:55am, Thursday, 19'th Sep 2024
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Corcept Therapeutics - Three Dynamic Catalysts To Reaccelerate Growth
11:40am, Sunday, 15'th Sep 2024
Corcept is a profitable midcap biotechnology company specializing in treating Cushing's Syndrome, with significant potential for revenue growth and expansion into other therapeutic areas. Recent stu
Corcept Shares Rise More Than 45% in Six Months: Here's Why
12:32pm, Tuesday, 03'rd Sep 2024
CORT's Cushing's syndrome drug, Korlym, has been performing well. The NDA for lead candidate, relacorilant, in Cushing's syndrome will be filed shortly.
